|
|
Biotech
|
|
||
Re: Pharvaris Shares Soar 79% on Hereditary Angioedema Treatment PHVS416 DataRoughly 50% of current value ($9.60) of PHVS is cash, or approx $4.50, which is estimated to be enough to get them to 2024. They are still working to lift FDA hold on PHA121, which is the company's lead candidate. |
return to message board, top of board |